Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27628753 | 0.87 | ALDH1A1 (0.47) | AOC3ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL335997 | 0.80 | ESR1 (0.36) | CYP2C9CYP2C19 | |
| SCHEMBL334855 | 0.80 | MC4R (0.38) | AOC3 | |
| SCHEMBL1133159 | 0.78 | PGR (0.36) | AOC3CYP2C19 | |
| SCHEMBL1132481 | 0.78 | TSHR (0.36) | ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1133167 | 0.77 | HTR2C (0.38) | ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL1132754 | 0.77 | TAAR1 (0.41) | AOC3ALDH1A1 | |
| SCHEMBL334999 | 0.77 | TAAR1 (0.41) | AOC3ALDH1A1 | |
| SCHEMBL1132864 | 0.76 | IDO1 (0.37) | ALDH1A1 | |
| SCHEMBL334284 | 0.76 | MC4R (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | AOC3 4508/4885ALDH1A1 1939/4885CYP1A2 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.